Zhejiang Medicine Co., Ltd. (600216.SS) Bundle
Who's buying Zhejiang Medicine Co., Ltd. (600216.SS) and why it matters: retail investors dominate with a striking 53% stake, while private companies hold roughly 24%, institutional investors account for about 18.84%, and venture capital/private equity firms control 15.8% - complemented by the National Social Security Fund's 8.19% and China Life's 5.30% positions; at the shareholder level Xinchang Changxin Investment Development Ltd. commands a powerful 22% stake with SDIC Hi‑tech at 15.8%, and smaller institutional holders such as Zhejiang Xianju Development (1.82%), Shanghai Ruiyang (0.95%), China Southern Asset Management (0.82%) and Yinhua Fund (0.59%) round out a mix that blends retail momentum, strategic corporate ownership and government/insurance backing-dig into the full profile to understand how these exact percentages shape governance, market sentiment and potential strategic moves.
Zhejiang Medicine Co., Ltd. (600216.SS) - Who Invests in Zhejiang Medicine Co., Ltd. (600216.SS) and Why?
Zhejiang Medicine Co., Ltd. attracts a diversified investor base driven by growth prospects in pharmaceuticals, steady dividend potential, strategic industry play, and policy-aligned institutional support. Ownership structure highlights the mix of retail, corporate, institutional and government-related capital that underpins the company's market positioning.- Individual investors: ~53% - strong retail interest in pharma growth stories and domestic healthcare plays.
- Private companies: ~24% - corporate strategic holdings and possible supply-chain/partnership synergies.
- Institutional investors: ~18.84% - mutual funds, asset managers showing moderate confidence and governance oversight.
- Venture capital & private equity: ~15.8% - growth-oriented stakes targeting product pipelines, M&A and value creation.
- National Social Security Fund: 8.19% - government-linked, long-term, stabilizing investor seeking social-returns and steady yield.
- China Life Insurance Co., Ltd.: 5.30% - major insurer allocating to stable, dividend-generating equities.
| Investor Type | Approx. Ownership | Primary Motivation |
|---|---|---|
| Individual (Retail) | 53% | Capital appreciation on drug approvals, speculation, dividend income |
| Private Companies | 24% | Strategic partnerships, vertical integration, commercial synergies |
| Institutional Investors | 18.84% | Portfolio diversification, governance influence, medium-term returns |
| Venture Capital / PE | 15.8% | High-growth investments, restructuring/M&A upside |
| National Social Security Fund | 8.19% | Long-term, stable returns; policy-aligned support |
| China Life Insurance | 5.30% | Liability-matching, stable dividend yield |
- Growth pipeline: investors expect new product launches and R&D conversion to revenue.
- Domestic healthcare demand: aging population and policy support for pharma spending.
- Margin and cash-flow stability: attractive to insurers and long-term funds.
- Strategic corporate logic: private companies seek supply-chain control or joint commercialization.
- Active PE/VC play: targetable operational improvements, roll-ups and eventual exits.
Zhejiang Medicine Co., Ltd. (600216.SS) Institutional Ownership and Major Shareholders of Zhejiang Medicine Co., Ltd. (600216.SS)
Zhejiang Medicine Co., Ltd. exhibits a concentrated and strategic institutional ownership profile, with several major shareholders controlling a meaningful portion of issued shares. The ownership mix combines state-backed investors, regional development vehicles, and professional asset managers - a structure that supports both stability and access to patient, long-term capital.- Xinchang Changxin Investment Development Ltd. - 22.00%: the largest single shareholder, providing a controlling anchor and signaling strong local/institutional confidence.
- SDIC Hi-tech Investment Co., Ltd. - 15.80%: substantial state-affiliated private-equity-style hold, reflecting strategic industrial investment motives.
- Zhejiang Xianju Development Holdings Co., Ltd. - 1.82%: regional development participation that aligns local government interests with corporate strategy.
- Shanghai Ruiyang Investment Management Co., Ltd. - 0.95%: active asset manager exposure supporting liquidity and market engagement.
- China Southern Asset Management Co., Ltd. - 0.82%: institutional fund management allocation for diversified portfolio exposure to healthcare.
- Yinhua Fund Management Co., Ltd. - 0.59%: smaller fund position representing continued institutional interest.
| Shareholder | Type | Stake (%) | Implication |
|---|---|---|---|
| Xinchang Changxin Investment Development Ltd. | Local/Strategic Investor | 22.00 | Control/long-term anchor shareholder |
| SDIC Hi-tech Investment Co., Ltd. | State-affiliated investor | 15.80 | Strategic industrial backing and capital stability |
| Zhejiang Xianju Development Holdings Co., Ltd. | Regional development company | 1.82 | Aligns municipal/regional economic goals |
| Shanghai Ruiyang Investment Management Co., Ltd. | Asset manager | 0.95 | Market liquidity and institutional monitoring |
| China Southern Asset Management Co., Ltd. | Fund manager | 0.82 | Portfolio diversification into healthcare equities |
| Yinhua Fund Management Co., Ltd. | Fund manager | 0.59 | Minor institutional stake, indicative of selective interest |
- Control and Governance: The 22% stake by Xinchang Changxin provides de facto governance influence, reducing hostile takeover risk and enabling strategic, long-horizon decisions.
- Strategic Capital & Industrial Policy: SDIC Hi-tech's 15.8% stake signals alignment with national/regional industrial strategies for biotech and pharmaceutical innovation.
- Regional Economic Integration: Local development holdings (e.g., Zhejiang Xianju) indicate municipal support for employment, R&D, and supply-chain localization.
- Portfolio Diversification: Asset managers and mutual funds (China Southern, Yinhua, Shanghai Ruiyang) hold sub-1% positions typical of institutional diversification into defensive/innovation-driven healthcare exposure.
- Stability vs. Liquidity Trade-off: Large strategic holders contribute to share-price stability; smaller fund positions provide tradability and continuous market interest.
- Long-term investment horizon is fostered by major state/strategic shareholders, supporting R&D and capital expenditure plans.
- Regulatory and policy alignment increases likelihood of preferential access to local resources and collaborative projects.
- Concentration risk: with ~37.8% held by the top two shareholders, minority investor liquidity and influence can be constrained.
- Institutional credibility: multiple reputable fund managers on the register enhance market confidence and can attract further institutional flows.
Zhejiang Medicine Co., Ltd. (600216.SS) Key Investors and Their Impact on Zhejiang Medicine Co., Ltd. (600216.SS)
Zhejiang Medicine's shareholder structure is anchored by a mix of a controlling local investor, significant state/strategic shareholders, and diversified institutional holders. Their stakes shape governance, capital allocation, partnership opportunities, and market perception.- Xinchang Changxin Investment Development Ltd. - 22.00%: dominant block with board influence and strategic direction control.
- SDIC Hi-tech Investment Co., Ltd. - 15.80%: large strategic/state-affiliated investor with potential to drive partnerships, R&D projects, and policy-aligned investments.
- Zhejiang Xianju Development Holdings Co., Ltd. - 1.82%: local development holding that diversifies the base and can support regional collaboration.
- Shanghai Ruiyang Investment Management Co., Ltd. - 0.95%: modest active asset manager position likely to engage on governance or performance triggers.
- China Southern Asset Management Co., Ltd. - 0.82%: institutional investor providing continuity and liquidity; may vote in line with long-term value creation.
- Yinhua Fund Management Co., Ltd. - 0.59%: additional institutional support, contributing to investor base depth.
| Investor | Reported Stake (%) | Relative Influence (1-5) | Primary Impact Channel |
|---|---|---|---|
| Xinchang Changxin Investment Development Ltd. | 22.00% | 5 | Board appointments, strategic M&A, capital allocation |
| SDIC Hi-tech Investment Co., Ltd. | 15.80% | 4 | Strategic partnerships, financing support, industry alliances |
| Zhejiang Xianju Development Holdings Co., Ltd. | 1.82% | 2 | Regional cooperation, stakeholder stability |
| Shanghai Ruiyang Investment Management Co., Ltd. | 0.95% | 2 | Active engagement, proxy voting, performance monitoring |
| China Southern Asset Management Co., Ltd. | 0.82% | 2 | Institutional voting, liquidity provision |
| Yinhua Fund Management Co., Ltd. | 0.59% | 1 | Portfolio allocation support, secondary-market demand |
- Governance dynamics: the 22% controlling block combined with SDIC Hi-tech's 15.8% creates a two-anchor shareholder structure-high capacity to steer board composition and strategic choices.
- Institutional layer: cumulative institutional stakes (~3.36% from the named fund managers) help stabilize trading, provide stewardship, and signal investor confidence to the market.
- Strategic implications: SDIC Hi-tech's presence increases likelihood of technology and R&D collaboration or state-driven industrial initiatives; Xinchang Changxin's control makes management continuity and long-horizon investments more probable.
Zhejiang Medicine Co., Ltd. (600216.SS) - Market Impact and Investor Sentiment
Zhejiang Medicine Co., Ltd. exhibits a mixed investor base whose composition materially shapes price action, liquidity, and strategic direction. Significant retail participation combined with targeted holdings from private companies, institutions, venture capital, and state-linked funds creates a dynamic where sentiment-driven moves coexist with strategic, long-term positioning.- Retail investors: 53.00% - dominant free-float influence on short-term volatility and trading volume.
- Private companies: 24.00% - potential for corporate partnerships, supply-chain alignment, or M&A interest.
- Institutions: 18.84% - moderate confidence from asset managers and funds that can stabilize longer-term price expectations.
- Venture capital & private equity: 15.80% - signals focus on growth initiatives, innovation funding, and value creation strategies.
- National Social Security Fund: 8.19% - state-affiliated stake that often confers perceived downside protection and credibility.
- China Life Insurance Co., Ltd.: 5.30% - large insurance investor contributing to balance-sheet confidence and demand for dividend/steady returns.
| Holder Type | Reported Stake (%) | Primary Market Impact |
|---|---|---|
| Retail Investors | 53.00 | High trading turnover; sentiment-driven swings; greater sensitivity to news/social channels |
| Private Companies | 24.00 | Strategic influence; potential for partnerships, vertical integration, or takeovers |
| Institutions | 18.84 | Anchoring of medium-to-long-term valuations; systematic buying/selling patterns |
| Venture Capital & Private Equity | 15.80 | Capital for R&D and expansion; exit-driven time horizons can affect volatility around milestones |
| National Social Security Fund | 8.19 | Perceived safety net; positive signaling to domestic and global investors |
| China Life Insurance Co., Ltd. | 5.30 | Long-term portfolio investor; supports dividend/credit perceptions |
Zhejiang Medicine Co., Ltd. (600216.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.